about
Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?[Validation of a new methodology for characterizing ultrasound contrast agents (UCA)]Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.Oxazaphosphorines: new therapeutic strategies for an old class of drugs.Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Dyslipidemia causes overestimation of plasma mitotane measurementsInsights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancerThe lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid developmentPharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.Efficacy and safety of gefitinib during pregnancy: case report and literature review.Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.Safety and efficacy compared between irinotecan-loaded microspheres HepaSphere and DC bead in a model of VX2 liver metastases in the rabbit.Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty.Physico-chemical stability of busulfan in injectable solutions in various administration packagesVariation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.Dual-mode gradient HPLC procedure for the simultaneous determination of chloroquine and proguanil.Stability of Melphalan in 0.9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection.Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.Microbiological and physicochemical stability of oxycodone hydrochloride solutions for patient-controlled delivery systems.Identification and quantitation of antineoplastic compounds in chemotherapeutic infusion bags by use of HPTLC: application to the vinca-alkaloids.Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products.Therapeutic drug monitoring in cancer--are we missing a trick?Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry.New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.Liquid chromatography-mass spectrometry assay for quantitation of ifosfamide and its N-deschloroethylated metabolites in rat microsomal medium.Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.Familial hematological malignancies: new IDH2 mutation.
P50
Q26766236-F4E5CE96-F3D1-479B-AA0F-B8474B3A5E2AQ33215567-910143C4-C64D-4470-8D74-1533D155F86AQ33345134-D96BBCBF-EC98-437C-928E-28E77CBD67E0Q33390217-B170EE10-0EE1-4B6F-A659-6D13F31C2BB0Q34041139-B3B050DD-E786-4EBD-8F68-6C714AA32EB2Q34113899-BF3153B5-1CA3-41F2-A87A-6E9AA57E5042Q36694926-1275BBA6-CFEC-48F8-8AF4-36E96CE0E742Q36694931-1344D110-DE9B-40F1-A087-DBD10D4189D0Q36990802-8CFA7466-63A2-44B9-BBC5-2886ADAA6FF6Q37203121-AB08E672-34B2-482C-A513-B7AAE8C39FC8Q37452556-CB5CEA9F-0E21-42E1-B9C0-02DFDCDFADF7Q37549960-02BE525A-6792-4B6F-B32B-999C6829A9E2Q38060264-A42CE44B-E7D9-439E-88C5-41B8F51B5310Q38220117-40E68D1F-E29B-4F25-9A17-4222571B71D9Q38226593-5493B459-CBEB-4C60-9F88-F9BBAFFB6B0CQ38774198-C5CA06B6-0D68-4435-B116-D53BE836E520Q38877965-C7DC3B3A-1202-44F2-9F58-9AAF6B180714Q38915625-B25FC5DD-8A63-4FD0-A745-21DE121BFB02Q38930156-7A1F7103-57FB-4447-9304-A3B2B4A7AAC4Q39006806-6FEA7995-8E0C-450B-9E9E-991E358F2BB4Q39187613-B1070A5B-2D6D-45FA-BB6B-280CBD4A4564Q39350915-B90A17E2-8649-412F-BCEA-36752D008A9DQ39861340-A41E6D40-BCA0-4CA1-B650-D42AA5ED8F5EQ41103420-FE5D6E7A-8E0C-4978-B358-78CEE7F24AC6Q41918574-D27B57AF-C7F9-40CD-A012-CC254B0E3703Q42147469-66030E9D-61C3-46E2-B0AB-B13159D669CDQ42997941-84E7CE02-AA15-4CF6-AA56-4A39394C7B8BQ43008925-B514088A-6BA3-4B69-B6F5-46BBA22F4D24Q44239865-F3D60760-2CE5-42E1-916D-9110DA6F09ACQ44770320-CBA77E46-997A-4C27-9370-B66FBBB0D14CQ44806188-44E92C12-569D-4280-BD1E-9077A191BE86Q44846620-DEB38C56-1E89-4C6E-B0B5-610D0B2F5513Q44884211-7529220A-4F50-4B26-BEAF-229E08A20947Q44939091-FD32B322-4E5E-4E6B-8774-3E1303EDDB5CQ45393730-610E2D3F-366D-4F88-9217-FEE6655AB814Q45997852-AFE2CE4D-E58A-45BF-A415-189537318204Q46239442-03819F11-534F-4168-B0A2-E9AD625F8122Q46495225-46D2F909-D232-471B-BDFD-4101CD38E921Q46599404-ABCBF105-835F-42BD-9450-FAAC6877E37EQ46677889-5B279785-4700-4F56-A7C8-8178850017A6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Paci
@ast
Angelo Paci
@en
Angelo Paci
@es
Angelo Paci
@nl
type
label
Angelo Paci
@ast
Angelo Paci
@en
Angelo Paci
@es
Angelo Paci
@nl
prefLabel
Angelo Paci
@ast
Angelo Paci
@en
Angelo Paci
@es
Angelo Paci
@nl
P106
P1153
55360357400
P21
P31
P496
0000-0002-4849-0825